文献速递泌尿男性生殖肿瘤

PROREPAIR-B:生殖系DNA修复突变对转移性去势抵抗性前列腺癌患者结局影响的前瞻性队列研究

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2019-01-09

这项前瞻性多中心队列研究在419例转移性去势抵抗性前列腺癌(mCRPC)患者中筛查107个基因的生殖系DNA损伤修复(gDDR)突变,携带率为16.2%(68例)。ATM/BRCA1/BRCA2/PALB2突变携带者与非携带者的病因特异性生存(CSS)无统计学显著差异(23.3 vs 33.2个月,P=0.264)。gBRCA2携带者CSS缩短(17.4 vs 33.2个月,P=0.027),且gBRCA2状态与一线治疗类型存在显著交互作用。

要点

  • ATM/BRCA1/BRCA2/PALB2突变携带者与非携带者CSS无统计学显著差异(23.3 vs 33.2个月,P=0.264)。
  • gBRCA2携带者CSS较非携带者缩短(17.4 vs 33.2个月,P=0.027),为CSS独立预后因素(HR 2.11,P=0.033)。
  • gBRCA2携带者一线使用阿比特龙或恩扎卢胺较紫杉类CSS(24.0 vs 17.0个月)和PFS2(18.9 vs 8.6个月)更长。

核心结论

  • gBRCA2突变对mCRPC结局有不良影响,且可能受一线治疗类型影响。
  • 检测gBRCA2状态可能有助于mCRPC初始治疗的选择,但需验证性研究后才能支持改变临床实践。

研究设计与样本

  • 前瞻性多中心队列研究,在mCRPC诊断时纳入未经选择的患者,筛查107个基因的gDDR突变。
  • 419例符合条件患者中识别出68例(16.2%)gDDR突变携带者,包括BRCA2 14例、ATM 8例、BRCA1 4例、PALB2 0例。
  • 主要目标是评估ATM/BRCA1/BRCA2/PALB2生殖系突变对mCRPC诊断起CSS的影响。
  • 次要目标包括gDDR亚组与mCRPC治疗缓解结局的关联,并探索从首个系统性治疗至第二个系统性治疗进展的联合无进展生存期(PFS2)。

主要发现

  • ATM/BRCA1/BRCA2/PALB2携带者与非携带者CSS无统计学显著差异(23.3 vs 33.2个月,P=0.264),研究未达到主要终点。
  • gBRCA2携带者CSS较非携带者缩短(17.4 vs 33.2个月,P=0.027),gBRCA2为CSS独立预后因素(HR 2.11,P=0.033)。
  • gBRCA2状态与治疗类型(雄激素信号抑制剂 vs 紫杉类)存在显著交互作用(CSS校正P=0.014;PFS2校正P=0.005)。
  • gBRCA2携带者一线使用阿比特龙或恩扎卢胺较紫杉类CSS更长(24.0 vs 17.0个月)、PFS2更长(18.9 vs 8.6个月)。
  • 非携带者中不同治疗类型的临床结局无差异。

临床怎么用

  • 作者认为gBRCA2状态检测可能有助于mCRPC初始治疗的选择。
  • 作者指出需验证性研究后才能支持改变临床实践。

局限性

  • 原文结论指出需验证性研究后才能支持改变临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes. PATIENTS AND METHODS: Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes. The primary aim was to assess the impact of ATM/BRCA1/BRCA2/ PALB2 germline mutations on cause-specific survival (CSS) from diagnosis of mCRPC. Secondary aims included the association of gDDR subgroups with response outcomes for mCRPC treatments. Combined progression-free survival from the first systemic therapy (PFS) until progression on the second systemic therapy (PFS2) was also explored. RESULTS: We identified 68 carriers (16.2%) of 419 eligible patients, including 14 with BRCA2, eight with ATM, four with BRCA1, and none with PALB2 mutations. The study did not reach its primary end point, because the difference in CSS between ATM/BRCA1/BRCA2/PALB2 carriers and noncarriers was not statistically significant (23.3 v 33.2 months; P = .264). CSS was halved in germline BRCA2 (g BRCA2) carriers (17.4 v 33.2 months; P = .027), and g BRCA2 mutations were identified as an independent prognostic factor for CCS (hazard ratio [HR], 2.11; P = .033). Significant interactions between g BRCA2 status and treatment type (androgen signaling inhibitor v taxane therapy) were observed (CSS adjusted P = .014; PFS2 adjusted P = .005). CSS (24.0 v 17.0 months) and PFS2 (18.9 v 8.6 months) were greater in g BRCA2 carriers treated in first line with abiraterone or enzalutamide compared with taxanes. Clinical outcomes did not differ by treatment type in noncarriers. CONCLUSION: g BRCA2 mutations have a deleterious impact on mCRPC outcomes that may be affected by the first line of treatment used. Determination of g BRCA2 status may be of assistance for the selection of the initial treatment in mCRPC. Nonetheless, confirmatory studies are required before these results can support a change in clinical practice.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Castro E, Romero-Laorden N, Del Pozo A, et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019. PMID: 30625039. doi:10.1200/JCO.18.00358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。